Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

CTX-10726

Phase 1Small molecule

CCompass Therapeutics

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastroesophageal Cancer (GC)Recruiting

Gastroesophageal Cancer (GC)Phase 1

Recruiting

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Gastroesophageal Cancer (GC)

NCT07419841

Clinical

Trials by Indication[1]

Gastroesophageal Cancer (GC)1 trial

A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-10726 in Patients With Advanced Malignancies

Recruiting·CCompass Therapeutics·Phase 1·NCT07419841·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CTX-10726. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CTX-10726 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CTX-10726. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Compass Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CCompass Therapeutics

Related News